Hepatitis C Virus (HCV)

all Activators (1) Inhibitors (254)

CAS No.	Product Name	Inquiry
2164516-85-0	Sofosbuvir impurity I Sofosbuvir impurity I is a diastereoisomer and impurity of Sofosbuvir, an inhibitor of HCV RNA replication with strong anti-hepatitis C virus activity.
2172676-02-5	Velpatasvir-[d7] Velpatasvir-[d7] is the labelled analogue of Velpatasvir, which is a selective Hepatitis C virus NS 5 protein inhibitor.
2189684-44-2	Lenacapavir Lenacapavir is a HIV-1 capsid inhibitor.
2241337-84-6	Bemnifosbuvir hemisulfate Bemnifosbuvir is the precursor drug form of the antiviral nucleoside analogue AT-9010. It reduces the infectious virus yield in cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome CoV (SARS-CoV), SARS-CoV-2, human CoV 229E (HCoV-229E), and HCoV-OC43 (EC90s = 37, 0.47, 2.8, 1.2, and 0.5 µM, respectively).
2425804-98-2	HCV-IN-37 HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage.
2425805-22-5	HCV-IN-34 HCV-IN-34 (compound 3i) is an orally active and potent HCV entry inhibitor. HCV-IN-35 shows excellent antiviral activity, with an EC50 of 0.010 μM and a CC50 (half-maximal cytotoxic concentration) of 8.23 μM.
2457357-99-0	FNC-TP FNC-TP is the intracellular active form of FNC which is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV.
2468169-71-1	HCV-IN-41 HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC50 value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication
254435-95-5	Alisporivir Alisporivir, also known as DEB-025, a non-immunosuppressive cyclosporine A derivative, is acyclophil ininhibitor molecule with potent anti-hepatitis C virus (HCV) activity. Treatment with alisporivir alone or combined with PEGylated IFNalpha2a reduced the viral load in patients with chronic HCV infection.
2649904-85-6	SMCypI-C31 SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction.
2653209-08-4	2'-O-Methylcytidine-d3
2734870-15-4	Emitasvir-diphosphate Emitasvir (DAG181) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection.
2757963-81-6	HCV-IN-36 HCV-IN-36 (compound (S)-3h) is an orally active and potent HCV entry inhibitor. HCV-IN-36 shows excellent antiviral activity, with an EC50 of 0.016 μM and a CC50 (half-maximal cytotoxic concentration) of 8.78 μM.
2757963-82-7	HCV-IN-35 HCV-IN-35 (Compound (R)-3h) is a potent inhibitor of HCV. HCV-IN-35 has the potential for the research infection diseases.
2757963-83-8	HCV-IN-33 HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor.
278603-08-0	NH125 NH125 is a potent and selective eEF-2 kinase inhibitor with an IC50 of 60 nM, and also a potent histidine kinase inhibitor. It shows >125-fold selectivity over PKC, PKA, and CaMKII.
290362-31-1	HCV-1 e2 Protein (554-569)
300832-84-2	Ciluprevir Ciluprevir is used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim Pharma GmbH & Co. kg and developed under the research code of BILN-2061. It is targeted against NS2-3 protease.
3039-71-2	U 18666A U 18666A is a cell-permeable and amphiphilic amino-steroid that inhibits cholesterol synthesis and cellular transport via the suppression of 2,3-oxidosqualene-lanosterol cyclase activity. U 18666A also acts as a weak inhibitor of hedgehog (Hh) signaling. It has been shown to reduce serum sterol levels in rats in vivo.
30652-11-0	Deferiprone A chelator that could replace disferrioxamine. It is orally and parenterally effective in the removal of iron in vivo from rabbits and mice and also from transferrin and ferritin in vitro.

※ Please kindly note that our services are for research use only.